Wir sind mit live! Mehr erfahren
CLOV-Symbol

Clover Health Investments

4,48 USD
-0,20
4,27 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
4,50
+0,02
0,45 %
1 Tag
-4,27 %
5 Tage
-6,28 %
1 Monat
-1,75 %
3 Monate
1,82 %
6 Monate
107,41 %
Seit Jahresbeginn
85,89 %
1 Jahr
65,93 %
5 Jahre
-43,22 %
10 Jahre
-56,08 %
 

Profil: Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

Mitarbeiter: 724

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 33,3 %
Neutral 61,1 %
Negativ 5,6 %
Neutral
GlobeNewsWire
vor 8 Tagen
Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
WILMINGTON, Del., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that the Centers for Medicare & Medicaid Services (“CMS”) has awarded its PPO Medicare Advantage (“MA”) plans a rating of 5 Stars and its HMO MA plan a rating of 4.5 Stars for 2027, which will affect payment year 2028.
Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
Neutral
GlobeNewsWire
vor 9 Tagen
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, November 4, 2026.
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
Neutral
GlobeNewsWire
vor 15 Tagen
Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
WILMINGTON, Del., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced its 2027 Medicare Advantage (MA) plan offerings, with a continued focus on PPO choice, affordable access to preventive care and meaningful member value.
Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
Neutral
GlobeNewsWire
vor 22 Tagen
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D.
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D.
Neutral
GlobeNewsWire
vor 22 Tagen
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D.
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D.
Positiv
MarketBeat
vor 28 Tagen
Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies' Healthcare Services and Technology Conference in Nashville.
Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens
Neutral
GlobeNewsWire
letzten Monat
Clover Health to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m.
Clover Health to Participate in Upcoming Investor Conferences
Positiv
Seeking Alpha
letzten Monat
Clover Health Is A 'Buy' Because Of Its AI
Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.
Clover Health Is A 'Buy' Because Of Its AI
Neutral
Seeking Alpha
vor 2 Monaten
Clover Health Investments: Real Turnaround, But Already Priced In
Clover Health Investments (CLOV) is rated Hold, with operational execution but a cautious outlook due to valuation and litigation risks. CLOV's Medicare Advantage membership grew 48% YoY, revenue and GAAP net income improved, but profitability per member lags FY2024 levels. FY2026 guidance implies negative H2 results; $120M in quality bonus revenue is at risk pending CMS litigation outcome.
Clover Health Investments: Real Turnaround, But Already Priced In
Positiv
Seeking Alpha
vor 2 Monaten
Clover Health Is Proving Its Profit Model
Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.
Clover Health Is Proving Its Profit Model
Kursdiagramme mit Lightweight Charts™ umgesetzt